High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide

The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourabdollah, Maryam, Bahmanyar, Mohammad, Atenafu, Eshetu G., Reece, Donna, Hou, Jian, Chang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120536/
https://www.ncbi.nlm.nih.gov/pubmed/27881177
http://dx.doi.org/10.1186/s13045-016-0354-2
_version_ 1782469261554352128
author Pourabdollah, Maryam
Bahmanyar, Mohammad
Atenafu, Eshetu G.
Reece, Donna
Hou, Jian
Chang, Hong
author_facet Pourabdollah, Maryam
Bahmanyar, Mohammad
Atenafu, Eshetu G.
Reece, Donna
Hou, Jian
Chang, Hong
author_sort Pourabdollah, Maryam
collection PubMed
description The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0354-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5120536
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51205362016-11-28 High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide Pourabdollah, Maryam Bahmanyar, Mohammad Atenafu, Eshetu G. Reece, Donna Hou, Jian Chang, Hong J Hematol Oncol Letter to the Editor The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0354-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-21 /pmc/articles/PMC5120536/ /pubmed/27881177 http://dx.doi.org/10.1186/s13045-016-0354-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Pourabdollah, Maryam
Bahmanyar, Mohammad
Atenafu, Eshetu G.
Reece, Donna
Hou, Jian
Chang, Hong
High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
title High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
title_full High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
title_fullStr High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
title_full_unstemmed High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
title_short High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
title_sort high ikzf1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120536/
https://www.ncbi.nlm.nih.gov/pubmed/27881177
http://dx.doi.org/10.1186/s13045-016-0354-2
work_keys_str_mv AT pourabdollahmaryam highikzf13proteinexpressionisafavorableprognosticfactorforsurvivalofrelapsedrefractorymultiplemyelomapatientstreatedwithlenalidomide
AT bahmanyarmohammad highikzf13proteinexpressionisafavorableprognosticfactorforsurvivalofrelapsedrefractorymultiplemyelomapatientstreatedwithlenalidomide
AT atenafueshetug highikzf13proteinexpressionisafavorableprognosticfactorforsurvivalofrelapsedrefractorymultiplemyelomapatientstreatedwithlenalidomide
AT reecedonna highikzf13proteinexpressionisafavorableprognosticfactorforsurvivalofrelapsedrefractorymultiplemyelomapatientstreatedwithlenalidomide
AT houjian highikzf13proteinexpressionisafavorableprognosticfactorforsurvivalofrelapsedrefractorymultiplemyelomapatientstreatedwithlenalidomide
AT changhong highikzf13proteinexpressionisafavorableprognosticfactorforsurvivalofrelapsedrefractorymultiplemyelomapatientstreatedwithlenalidomide

Ejemplares similares